October 3, 2017
All of the diverse operations of Verily, the life sciences technology company that began its life as Google X Life Sciences, can be summed up with a simple sentence: We should be treating our bodies at least as well as we treat our cars.
At the Health 2.0 Fall Conference in Santa Clara this week, Verily Chief Technology Officer Brian Otis spoke with Health 2.0 cofounder and CEO Dr. Indu Subaya on...
September 26, 2017
Just two months after announcing the applications for its pre-certification program pilot, the FDA has announced the nine companies that will be participating. The list includes major tech companies Apple and Samsung; health tech companies Verily, Pear Therapeutics, Tidepool, and Phosphorus; pharmaceutical companies Roche and Johnson & Johnson; and Fitbit — an interesting inclusion insofaras...
August 7, 2017
The University of North Carolina is tapping Google's Verily Life Sciences and MindStrong (the company for which Dr. Thomas Insell recently left Verily) for an ambitious 19-site study of post-traumatic stress disorder. The study, called the Aurora Study, is funded by a $21 million NIH grant and aims to enroll 5,000 people.
Aurora was launched last September and has sought private funding to...
August 3, 2017
DexCom hasn’t been shy about its plan for opening up the CGM market by encouraging CGM use in a wider group of people with diabetes — including, eventually, people with Type 2 diabetes. On its second quarter earnings call, the company went deep on that focus on the future.
“More and more people with diabetes are adopting CGM that as the primary tool to manage their condition, especially as we...
June 19, 2017
Mindstrong Health, the mental health startup that former NIMH director Dr. Thomas Insel left Verily for last month, has raised $14 million. Foresite Capital and ARCH Venture Partners led the round, with additional participation from Optum Ventures, Berggruen Holdings, and the One Mind Brain Health Impact Fund.
Although it has been reported that Insel left Verily to start Mindstrong, the startup...
May 19, 2017
The days of claiming artificial intelligence as a feature that set one startup or company apart from the others are over. These days, one would be hard-pressed to find any technology company attracting venture funding or partnerships that doesn’t posit to use some form of machine learning. But for companies trying to innovate in healthcare using artificial intelligence, the stakes are...
May 18, 2017
As Scott Gottlieb kicks off his tenure as FDA commissioner, former commissioner Robert Califf has a new gig as well. Califf revealed in a blog post that he has taken a job at Verily, the life sciences arm of Alphabet, as well as returning to professorial positions at Duke and Stanford. Although the details of his role are still unclear, Califf will work on Verily’s Baseline study, an effort to...
May 11, 2017
Roy J.E.M. Raymann, who, as we reported yesterday, left Apple's sleep team a month ago, has moved to SleepScore Labs, a joint venture between ResMed, Dr. Oz Media, and Pegasus Capital Advisors. He will serve as Vice President of Sleep Science and Scientific Affairs.
First announced this year at CES, SleepScore Labs is "currently in the process of examining how people sleep by compiling and...
May 10, 2017
Dr. Thomas Insel, former director of the National Institute of Mental Health, has left Verily after a little under two years. According to a report in Nature, Insel will be starting a new startup called Mindstrong that will be focused on using smartphones to detect mental health conditions.
Insel joined Verily, a subsidiary of Alphabet that at the time was called Google Life Sciences, in...
April 20, 2017
Alphabet-owned Verily has launched the Project Baseline Study, a collaborative effort with Stanford Medicine and Duke University School of Medicine to amass a large collection of broad phenotypic health data in hopes of developing a well-defined reference of human health.
Project Baseline aims to gather data from around 10,000 participants, each of whom will be followed for four years, and will...